We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Improved Medical Imaging and Drug Development May Result from Reference Isotope

By Biotechdaily staff writers
Posted on 28 Jan 2008
An increasingly popular radioactive isotope now has its own reference stand-in. More...
The isotope may ultimately improve medical imaging, speed up clinical trials of many drugs, and facilitate efforts to develop more individualized medical treatment.

The number of medical images obtained through the technique known as positron emission tomography (PET) imaging is increasing at a rate of 20% per year, and this has correspondingly increased the use of fluorine-18, the radioactive isotope of choice in the vast majority of PET procedures. Injected into the bloodstream while bound to "carrier” molecules, fluorine-18 lights up the body during PET scans to perform such tasks as revealing tumors, tracking heart activity, and determining which regions of the brain are active during specific tasks.

However, fluorine-18 has a very short life --a batch of the compound decays to half its initial quantity in fewer than two hours, and less than one ten-thousandth of the original amount is left after a single day. Because the isotope decays so rapidly, it is not possible for a single central lab to make precise measurements on fluorine-18 solutions and then distribute them to remote centers to calibrate PET machines. This lack of a "standard reference” for fluorine-18 means that PET-related measurements from center to center, from patient to patient, and even in the same patient over time, are difficult or impossible to compare with one another.

Researchers from the U.S. National Institute of Standards and Technology (NIST; Gaithersburg, MD, USA) collaborating with a nuclear medicine company called RadQual (Concord, NH, USA), have looked to germanium-68 as a calibration surrogate for fluorine-18. This germanium isotope is much longer lived--its half-life is 270.95 days--but its radiation decay characteristics are otherwise similar to fluorine-18. Small differences between measurements of germanium-68 and fluorine-18 can be accounted for through the use of mathematic conversion factors. Germanium-68 never would be used in actual PET procedures; it would only be used to calibrate the machines properly, enabling more accurate measurements of the fluorine-18 isotopes. Although germanium-68 has been used for performing corrections on PET scanners, the industry has lacked a traceable standard reference material for instrument calibration.

NIST researchers have calibrated solutions of germanium-68 that could become the basis of a new standard reference material for this isotope. The next phase of this project involves working with RadQual to calibrate a new "mock” syringe standard that would use germanium-68 embedded in an epoxy to simulate fluorine-18 in a syringe. This would help researchers more accurately determine the amount of fluorine-18 to be injected into patients during the PET procedure so as to minimize radiation dose while still generating the best image. NIST is also working independently on a germanium-68-based PET "phantom” that can be used to calibrate PET scanners in a way that is traceable back to NIST.

The first commercial products from this collaboration may be reaching PET centers later in 2008. By giving clinicians more effective results on how specific patients are responding to cancer treatments and providing more accurate indications earlier in clinical trials as to how individual patients are metabolizing specific drugs, better standards for PET imaging may hasten the arrival of customized medicine.


Related Links:
National Institute of Standards and Technology
RadQual

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
DNA Extraction Kit
MagMAX DNA Multi-Sample Ultra 2.0 Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.